Skip to main content

Advertisement

Table 2 Clinical and pathological data for breast tumours in the independent validation cohort

From: MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neureceptor status in breast cancer

Breast cancer clinicopathological characteristic Number of patients (n = 95)
Median (interquartile range) tumour size (mm) 23.5 (17.75 to 35.0)
Histologic subtype  
   Invasive ductal 80
   Invasive lobular 13
   Colloid/mucinous 1
   Tubular 1
   Tumour-associated normal 17
Intrinsic subtype  
   Luminal A (ER/PR+, HER2/neu-) 47
   Luminal B (ER/PR+, HER2/neu+) 21
   Her2 overexpressing (ER-, PR-, HER2/neu+) 11
   Triple-negative (ER-, PR-, HER2/neu-) 11
   Missing data 5
Grade  
   1 14
   2 26
   3 53
   Missing data 2
Nodal status  
   Node-negative 50
   N1 17
   N2 17
   N3 11
Oestrogen receptor status  
   Positive 62
   Negative 32
   Missing data 1
Progesterone receptor status  
   Positive 58
   Negative 33
   Missing data 4
Her2/neu status  
   Positive 32
   Negative 59
   Missing data 4
UICC stage  
   Stage 1 23
   Stage 2a 29
   Stage 2b 8
   Stage 3a 14
   Stage 3b 4
   Stage 3c 8
   Stage 4 9
  1. ER, oestrogen receptor; HER2/neu, v-erb-b2 erythroblastic leukaemia viral oncogene homolog 2 receptors; PR, progesterone receptor; UICC, stage of breast tumour according to the international union against cancer staging criteria.